PMID- 29684505
OWN - NLM
STAT- MEDLINE
DCOM- 20190405
LR  - 20211204
IS  - 1873-7544 (Electronic)
IS  - 0306-4522 (Linking)
VI  - 381
DP  - 2018 Jun 15
TI  - Protective Effects of Sulforaphane on Cognitive Impairments and AD-like Lesions 
      in Diabetic Mice are Associated with the Upregulation of Nrf2 Transcription 
      Activity.
PG  - 35-45
LID - S0306-4522(18)30268-9 [pii]
LID - 10.1016/j.neuroscience.2018.04.017 [doi]
AB  - Type 2 diabetes mellitus (T2DM)-associated oxidative stress contributes to 
      cognitive deficiencies and Alzheimer's disease (AD). Sulforaphane (SFN) is a 
      pharmacological activator of Nrf2 that provokes Nrf2-mediated intracellular 
      defenses, including antioxidant and anti-inflammatory responses, under oxidative 
      stress (OS) conditions. This study investigated the effects of SFN on DM-related 
      cognitive decline and its potential mechanisms. Morris water maze (MWM) tests 
      showed that SFN (1 mg/kg i.p. for 28 days) mitigated the cognitive decline of 
      db/db mice, a transgenic mouse model of T2DM. Accordingly, immunoblotting and 
      immunohistochemistry analyses showed that SFN decreased the levels of amyloid-beta 
      (Abeta) oligomers and Abeta 1-42 plaques as well as phospho-tau at Ser396 and Thr231 in 
      the DM mouse hippocampus. This protective effect of SFN might be due to the 
      activation of Nrf2-regulated antioxidant defense deficiencies in the DM mice, as 
      SFN increased the Nrf2 nuclear accumulation and the downstream expression of the 
      antioxidases HO-1 and NQO1 and reduced the levels of the reactive oxygen/nitrogen 
      species (ROS/RNS) in DM mouse brains. Our results confirm that SFN has potential 
      as a therapeutic agent to protect T2DM patients from cognitive deficiencies and 
      AD-like pathological lesions related to the upregulation of Nrf2-regulated 
      antioxidant defenses.
CI  - Copyright (c) 2018 IBRO. Published by Elsevier Ltd. All rights reserved.
FAU - Pu, Die
AU  - Pu D
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Zhao, Yuxing
AU  - Zhao Y
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Chen, Jinliang
AU  - Chen J
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Sun, Yue
AU  - Sun Y
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Lv, Ankang
AU  - Lv A
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Zhu, Shiyu
AU  - Zhu S
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Luo, Cheng
AU  - Luo C
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Zhao, Kexiang
AU  - Zhao K
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China.
FAU - Xiao, Qian
AU  - Xiao Q
AD  - Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical 
      University, China. Electronic address: xiaoqian1956@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180421
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
RN  - 0 (Antioxidants)
RN  - 0 (Isothiocyanates)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Nfe2l2 protein, mouse)
RN  - 0 (Sulfoxides)
RN  - GA49J4310U (sulforaphane)
SB  - IM
MH  - Alzheimer Disease
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Cognitive Dysfunction/*etiology/pathology
MH  - Diabetes Mellitus, Experimental/complications/pathology
MH  - Diabetes Mellitus, Type 2/*complications/pathology
MH  - Hippocampus/drug effects/*pathology
MH  - Isothiocyanates/*pharmacology
MH  - Male
MH  - Mice
MH  - NF-E2-Related Factor 2/*metabolism
MH  - Sulfoxides
MH  - Up-Regulation
OTO - NOTNLM
OT  - Abeta pathology
OT  - dementia
OT  - diabetic encephalopathy
OT  - oxidative stress
OT  - sulforaphane
OT  - tau hyperphosphorylation
EDAT- 2018/04/24 06:00
MHDA- 2019/04/06 06:00
CRDT- 2018/04/24 06:00
PHST- 2018/02/24 00:00 [received]
PHST- 2018/04/06 00:00 [revised]
PHST- 2018/04/11 00:00 [accepted]
PHST- 2018/04/24 06:00 [pubmed]
PHST- 2019/04/06 06:00 [medline]
PHST- 2018/04/24 06:00 [entrez]
AID - S0306-4522(18)30268-9 [pii]
AID - 10.1016/j.neuroscience.2018.04.017 [doi]
PST - ppublish
SO  - Neuroscience. 2018 Jun 15;381:35-45. doi: 10.1016/j.neuroscience.2018.04.017. 
      Epub 2018 Apr 21.